Global Vaccine and Immunization Research Forum
The Global Vaccine and Immunization Research Forum — co-hosted by WHO, the United States National Institute of Allergy and Infectious Diseases, and the Bill & Melinda Gates Foundation — will take place from 4-6 March 2014 in Maryland, USA. The Forum will bring together researchers, public health professionals and other key stakeholders to discuss progress and challenges in vaccine development and implementation research as identified in the Global Vaccine Action Plan.
The Forum will track progress on research, identify actions recommended to be taken forward by the research and development community, and provide opportunities for networking and collaborations across scientific and geographic boundaries.
Malaria Vaccine Technology Roadmap
The updated Malaria Vaccine Technology Roadmap represents the result of a review process facilitated by WHO, which worked with the Malaria Vaccine Funders Group to update the 2006 roadmap’s vision and strategic goals. The roadmap forms a strategic framework that underpins the activities of the global malaria vaccine research and development community. The updated document maintains the original goal of having a licensed vaccine against Plasmodium falciparum malaria by 2015, and sets a new goal of having a second generation of malaria vaccines licensed by 2030.
13th Dengue International Course open for registration
WHO/PAHO Collaborating Center for the Study of Dengue and its Vector, is organizing the 13th Dengue International Course from 12 to 23 August 2013 in La Habana, Cuba.
This two-week course includes lectures, seminars and practical sessions on laboratory diagnosis, clinical care, epidemiology, vector control and community participation activities. In addition, there will be symposia dedicated to dengue diagnosis, dengue clinical management, vaccine development and dengue surveillance among others.
The meningococcal A conjugate vaccine known as MenAfriVac® can now be kept in a controlled temperature chain at temperatures of up to 40°C for up to four days. With this new regulatory approval, this innovative vaccine, which costs less than US$0.50 per dose, could help increase vaccination campaign efficiency and coverage.